journal
https://read.qxmd.com/read/38782005/virological-characteristics-of-the-sars-cov-2-kp-2-variant
#21
LETTER
Yu Kaku, Keiya Uriu, Yusuke Kosugi, Kaho Okumura, Daichi Yamasoba, Yoshifumi Uwamino, Jin Kuramochi, Kenji Sadamasu, Kazuhisa Yoshimura, Hiroyuki Asakura, Mami Nagashima, Jumpei Ito, Kei Sato
No abstract text is available yet for this article.
May 20, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38768618/a-bedaquiline-pretomanid-moxifloxacin-and-pyrazinamide-regimen-for-drug-susceptible-and-drug-resistant-tuberculosis
#22
JOURNAL ARTICLE
Guofang Deng, Liang Fu
No abstract text is available yet for this article.
May 17, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38768617/bedaquiline-pretomanid-moxifloxacin-pyrazinamide-for-drug-sensitive-and-drug-resistant-pulmonary-tuberculosis-treatment-a-phase-2c-open-label-multicentre-partially-randomised-controlled-trial
#23
JOURNAL ARTICLE
Muge Cevik, Lindsay C Thompson, Caryn Upton, Valéria Cavalcanti Rolla, Mookho Malahleha, Blandina Mmbaga, Nosipho Ngubane, Zamzurina Abu Bakar, Mohammed Rassool, Ebrahim Variava, Rodney Dawson, Suzanne Staples, Umesh Lalloo, Cheryl Louw, Francesca Conradie, Marika Eristavi, Anastasia Samoilova, Sergey N Skornyakov, Niyanda Elias Ntinginya, Frederick Haraka, George Praygod, Harriett Mayanja-Kizza, Janice Caoili, Vincent Balanag, Margareth Pretti Dalcolmo, Timothy McHugh, Robert Hunt, Priya Solanki, Anna Bateson, Angela M Crook, Stella Fabiane, Juliano Timm, Eugene Sun, Melvin Spigelman, Derek J Sloan, Stephen H Gillespie
BACKGROUND: The current tuberculosis (TB) drug development pipeline is being re-populated with candidates, including nitroimidazoles such as pretomanid, that exhibit a potential to shorten TB therapy by exerting a bactericidal effect on non-replicating bacilli. Based on results from preclinical and early clinical studies, a four-drug combination of bedaquiline, pretomanid, moxifloxacin, and pyrazinamide (BPaMZ) regimen was identified with treatment-shortening potential for both drug-susceptible (DS) and drug-resistant (DR) TB...
May 17, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38761806/relative-vaccine-protection-disease-severity-and-symptoms-associated-with-the-sars-cov-2-omicron-subvariant-ba-2-86-and-descendant-jn-1-in-denmark-a-nationwide-observational-study
#24
JOURNAL ARTICLE
Ida Rask Moustsen-Helms, Peter Bager, Tine Graakjær Larsen, Frederik Trier Møller, Lasse Skafte Vestergaard, Morten Rasmussen, Christian Holm Hansen
BACKGROUND: During the 2023 Danish COVID-19 vaccination campaign, an updated monovalent mRNA vaccine targeting the SARS-CoV-2 omicron XBB.1.5 subvariant was administered. However, the rapid spread of a genetically divergent omicron BA.2.86 subvariant, JN.1, since September, 2023, poses potential challenges due to its rapid dominance and possible immune escape. Using national electronic health registry data from all regions of Denmark, we aimed to investigate whether the SARS-CoV-2 subvariant BA...
May 15, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38761805/immune-evasiveness-of-sars-cov-2-variants-and-vaccine-selection
#25
JOURNAL ARTICLE
Malin Inghammar, Fredrik Kahn
No abstract text is available yet for this article.
May 15, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38734013/rapid-diagnostic-tests-for-lassa-fever-what-do-we-aim-for
#26
JOURNAL ARTICLE
Mirjam Groger, Michael Ramharter
No abstract text is available yet for this article.
May 8, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38734012/field-evaluation-of-validity-and-feasibility-of-pan-lassa-rapid-diagnostic-test-for-lassa-fever-in-abakaliki-nigeria-a-prospective-diagnostic-accuracy-study
#27
JOURNAL ARTICLE
Jelte Elsinga, Temmy Sunyoto, Letizia di Stefano, Pier Francesco Giorgetti, Htet Aung Kyi, Chiara Burzio, Ximena Campos Moreno, Chiedozie K Ojide, Nnennaya Ajayi, Richard Ewah, Emeka O Ogah, Chioma Dan-Nwafor, Anthony Ahumibe, Chinwe Lucia Ochu, Adebola Olayinka, Sylvie Jonckheere, Pascale Chaillet, Michel van Herp
BACKGROUND: Lassa fever is a viral haemorrhagic fever with few options for diagnosis and treatment; it is also under-researched with knowledge gaps on its epidemiology. A point-of-care bedside test diagnosing Lassa fever, adhering to REASSURED criteria, is not currently available but is urgently needed in west African regions with high Lassa fever burden. We aimed to assess the validity and feasibility of a rapid diagnostic test (RDT) to confirm Lassa fever in people in Nigeria. METHODS: We estimated the diagnostic performance of the ReLASV Pan-Lassa RDT (Zalgen Labs, Frederick, MD, USA) as a research-use-only test, compared to RT-PCR as a reference standard, in 217 participants at a federal tertiary hospital in Abakaliki, Nigeria...
May 8, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38734010/urgent-considerations-for-booster-vaccination-strategies-against-ebola-virus-disease
#28
REVIEW
Wim Adriaensen, Selien Oostvogels, Yves Levy, Bailah Leigh, Hugo Kavunga-Membo, Deborah Watson-Jones
With two endorsed and prophylactic vaccines against Zaire ebolavirus (referred to hereafter as EBOV), the number of individuals vaccinated against EBOV worldwide is estimated to range between 500 000 and 1 000 000 individuals, increasing with every renewed EBOV threat and vaccination campaign. Therefore, re-exposure of previously vaccinated health-care workers, and possibly community members, could become more frequent. In the absence of long-term data on vaccine efficacy and duration of protection, we urgently need to understand revaccination strategies that could maximise the level of protection...
May 8, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38734009/evaluation-of-a-single-dose-hpv-vaccine-strategy-for-promoting-vaccine-health-and-gender-equity
#29
REVIEW
Mathew Mercuri, Kristy Hackett, Ruanne V Barnabas, Claudia I Emerson
Although several countries have adopted a single-dose human papillomavirus (HPV) vaccination strategy, many other countries continue to include multiple doses in their vaccination programmes. There are ethical reasons to transition to a single-dose strategy. We discuss how a single-dose HPV vaccination strategy advances equity in three dimensions: vaccine equity, health equity, and gender equity. Adopting a single-dose strategy eases pressure on vaccine supply, lowers programme costs, and is easier to distribute...
May 8, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38723652/ceftriaxone-resistance-in-neisseria-gonorrhoeae-associated-with-the-pena-60-001-allele-in-hanoi-viet-nam
#30
LETTER
Paul C Adamson, Vu N Hieu, Pham H Nhung, D M Whiley, T M Chau
No abstract text is available yet for this article.
May 6, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38723651/correction-to-lancet-infect-dis-2024-published-online-april-3-https-doi-org-10-1016-s1473-3099-24-00142-7
#31
(no author information available yet)
No abstract text is available yet for this article.
May 6, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38723650/genotypic-analysis-of-rts-s-as01-e-malaria-vaccine-efficacy-against-parasite-infection-as-a-function-of-dosage-regimen-and-baseline-malaria-infection-status-in-children-aged-5-17-months-in-ghana-and-kenya-a-longitudinal-phase-2b-randomised-controlled-trial
#32
JOURNAL ARTICLE
Michal Juraska, Angela M Early, Li Li, Stephen F Schaffner, Marc Lievens, Akanksha Khorgade, Brian Simpkins, Nima S Hejazi, David Benkeser, Qi Wang, Laina D Mercer, Samuel Adjei, Tsiri Agbenyega, Scott Anderson, Daniel Ansong, Dennis K Bii, Patrick B Y Buabeng, Sean English, Nicholas Fitzgerald, Jonna Grimsby, Simon K Kariuki, Kephas Otieno, François Roman, Aaron M Samuels, Nelli Westercamp, Christian F Ockenhouse, Opokua Ofori-Anyinam, Cynthia K Lee, Bronwyn L MacInnis, Dyann F Wirth, Peter B Gilbert, Daniel E Neafsey
BACKGROUND: The first licensed malaria vaccine, RTS,S/AS01E , confers moderate protection against symptomatic disease. Because many malaria infections are asymptomatic, we conducted a large-scale longitudinal parasite genotyping study of samples from a clinical trial exploring how vaccine dosing regimen affects vaccine efficacy. METHODS: Between Sept 28, 2017, and Sept 25, 2018, 1500 children aged 5-17 months were randomly assigned (1:1:1:1:1) to receive four different RTS,S/AS01E regimens or a rabies control vaccine in a phase 2b open-label clinical trial in Ghana and Kenya...
May 6, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38723649/asymptomatic-parasitemia-and-rts-s-vaccine-efficacy
#33
JOURNAL ARTICLE
Nobuko Arisue, Nirianne Marie Q Palacpac
No abstract text is available yet for this article.
May 6, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38710191/oral-antivirals-for-acute-symptoms-and-post-acute-sequelae-in-sars-cov-2-infection
#34
JOURNAL ARTICLE
Vicente Soriano, Víctor Moreno-Torres
No abstract text is available yet for this article.
May 3, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38710190/association-of-nirmatrelvir-ritonavir-with-post-acute-sequelae-and-mortality-in-patients-admitted-to-hospital-with-covid-19-a-retrospective-cohort-study
#35
JOURNAL ARTICLE
Huwen Wang, Yuchen Wei, Chi Tim Hung, Guozhang Lin, Xiaoting Jiang, Conglu Li, Katherine Min Jia, Carrie Ho Kwan Yam, Tsz Yu Chow, Janice Ying-En Ho, Yawen Wang, Shi Zhao, Zihao Guo, Kehang Li, Aimin Yang, Chris Ka Pun Mok, David S C Hui, Eng Kiong Yeoh, Ka Chun Chong
BACKGROUND: Studies have established the short-term efficacy of nirmatrelvir-ritonavir in managing COVID-19, yet its effect on post-COVID-19 condition, especially in patients admitted to hospital, remains understudied. This study aimed to examine the effect of nirmatrelvir-ritonavir on post-COVID-19 condition among patients admitted to hospital in Hong Kong. METHODS: This retrospective cohort study used real-world, territory-wide inpatient records, vaccination records, and confirmed COVID-19 case data from the Hong Kong Hospital Authority and Department of Health, The Government of the Hong Kong Special Administrative Region...
May 3, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38703785/shifting-transmission-patterns-of-human-mpox-in-south-kivu-dr-congo
#36
LETTER
Patrick Dmc Katoto, Winters Muttamba, Esto Bahizire, Espoir Bwenge Malembaka, Henry Kyobe Bosa, Dieudonné Mwamba Kazadi, Gaston Lubambo, Freddy Belesi Siangoli, Barnabas Bakamutumaho, Misaki Wayengera, Don Jethro Mavungu Landu, Daniel Mukadi-Bamuleka, Placide Mbala, Mark Loeb, Bruce Kirenga, Jean-Jacques Muyembe-Tamfum
No abstract text is available yet for this article.
May 1, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38701823/effectiveness-and-impact-of-universal-prophylaxis-with-nirsevimab-in-infants-against-hospitalisation-for-respiratory-syncytial-virus-in-galicia-spain-initial-results-of-a-population-based-longitudinal-study
#37
JOURNAL ARTICLE
Sonia Ares-Gómez, Narmeen Mallah, María-Isolina Santiago-Pérez, Jacobo Pardo-Seco, Olaia Pérez-Martínez, María-Teresa Otero-Barrós, Nuria Suárez-Gaiche, Rolf Kramer, Jing Jin, Leticia Platero-Alonso, Rosa-María Alvárez-Gil, Olga-María Ces-Ozores, Victoria Nartallo-Penas, Susana Mirás-Carballal, Marta Piñeiro-Sotelo, Alberto Malvar-Pintos, Juan-Manuel González-Pérez, Carmen Rodríguez-Tenreiro-Sánchez, Irene Rivero-Calle, Antonio Salas, Carmen Durán-Parrondo, Federico Martinón-Torres
BACKGROUND: Galicia (Spain) was one of the first regions worldwide to incorporate nirsevimab for universal respiratory syncytial virus (RSV) prophylaxis in infants into its immunisation programme. The NIRSE-GAL longitudinal population-based study aimed to assess nirsevimab effectiveness in preventing hospitalisations (ie, admittance to hospital). METHODS: The 2023-24 immunisation campaign with nirsevimab in Galicia began on Sept 25, 2023, and concluded on March 31, 2024...
April 30, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38701822/reporting-of-deaths-during-cholera-outbreaks-case-fatality-ratio-and-community-deaths
#38
LETTER
Flavio Finger, Kristen Heitzinger, David Berendes, Iza Ciglenecki, Morgane Dominguez, Kate Alberti, Emmanuel Baron, Philippe Barboza
No abstract text is available yet for this article.
April 30, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38701821/early-life-respiratory-syncytial-virus-disease-a-preventable-burden
#39
JOURNAL ARTICLE
Cheryl Cohen, Heather J Zar
No abstract text is available yet for this article.
April 30, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38697185/correction-to-lancet-infect-dis-2019-19-1380
#40
(no author information available yet)
No abstract text is available yet for this article.
April 29, 2024: Lancet Infectious Diseases
journal
journal
20187
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.